Tectonic Therapeutic, Inc. (TECX)
30.40
-0.82
(-2.63%)
USD |
NASDAQ |
Sep 02, 16:00
30.40
0.00 (0.00%)
After-Hours: 18:41
Tectonic Therapeutic Enterprise Value : 377.85M for Sept. 1, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 01, 2026 | 377.85M |
| August 31, 2026 | 353.23M |
| August 28, 2026 | 462.49M |
| August 27, 2026 | 483.26M |
| August 26, 2026 | 469.22M |
| August 25, 2026 | 502.69M |
| August 24, 2026 | 478.84M |
| August 21, 2026 | 501.15M |
| August 20, 2026 | 470.76M |
| August 19, 2026 | 489.80M |
| August 18, 2026 | 481.53M |
| August 17, 2026 | 428.44M |
| August 14, 2026 | 448.83M |
| August 13, 2026 | 430.94M |
| August 12, 2026 | 485.76M |
| August 11, 2026 | 390.36M |
| August 10, 2026 | 406.51M |
| August 07, 2026 | 373.24M |
| August 06, 2026 | 358.62M |
| August 05, 2026 | 345.92M |
| August 04, 2026 | 338.42M |
| August 03, 2026 | 314.38M |
| July 31, 2026 | 316.49M |
| July 30, 2026 | 325.73M |
| July 29, 2026 | 324.19M |
| Date | Value |
|---|---|
| July 28, 2026 | 350.54M |
| July 27, 2026 | 366.12M |
| July 24, 2026 | 361.50M |
| July 23, 2026 | 385.36M |
| July 22, 2026 | 384.97M |
| July 21, 2026 | 408.25M |
| July 20, 2026 | 394.20M |
| July 17, 2026 | 404.40M |
| July 16, 2026 | 366.89M |
| July 15, 2026 | 402.48M |
| July 14, 2026 | 446.91M |
| July 13, 2026 | 437.87M |
| July 10, 2026 | 438.44M |
| July 09, 2026 | 455.76M |
| July 08, 2026 | 459.80M |
| July 07, 2026 | 480.09M |
| July 06, 2026 | 454.79M |
| July 02, 2026 | 506.92M |
| July 01, 2026 | 407.09M |
| June 30, 2026 | 438.54M |
| June 29, 2026 | 390.84M |
| June 26, 2026 | 370.12M |
| June 25, 2026 | 352.05M |
| June 24, 2026 | 346.21M |
| June 23, 2026 | 343.76M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 4.090B |
| Alnylam Pharmaceuticals, Inc. | 32.59B |
| Anika Therapeutics, Inc. | 269.35M |
| Savara, Inc. | 956.26M |
| Vericel Corp. | 2.005B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -22.28M |
| Total Expenses (Quarterly) | 22.28M |
| EPS Diluted (Quarterly) | -1.175 |
| Earnings Yield | -15.01% |
| Normalized Earnings Yield | -15.01 |